Vertex Q2 revenue +12.5% to $3.33B; $10B Crinetics deal and ALYFTREK arbitration loom

Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read

Key Changes

• high

  Vertex agreed to acquire Crinetics Pharmaceuticals for $10.0B in cash, adding an approved acromegaly drug and Phase 3 pipeline; deal expected to close Q3 2026.

  MD&A: Crinetics acquisition verify on EDGAR →
• high

  Royalty Pharma initiated confidential arbitration alleging ALYFTREK royalty burden is ~8% vs Vertex's 4%; Vertex intends to defend vigorously.

  Notes: Royalty Pharma arbitration view on EDGAR →
• high

  CASGEVY revenue grew 151% YoY to $76.4M and JOURNAVX grew >300% to $49.6M in Q2 2026, with JOURNAVX prescriptions reaching 900,000 in H1.

  MD&A: Product revenue verify on EDGAR →